BMC Cancer: Western real-world data adds evidence for the efficacy of immune checkpoint inhibitors in previously treated patients with metastatic gastric cancer

Immune checkpoint inhibitor therapy in Asian population with metastatic diseaseEfficacy and safety in gastric cancer patients have been proven, but the efficacy and safety in the western real world are still lacking
.
Therefore, a multicenter retrospective real-world study was carried out abroad to evaluate the efficacy and safety of immune checkpoint inhibitors in Western patients with previously treated metastatic gastric cancer

.

Immune checkpoint inhibitor therapy in Asian population with metastatic diseaseEfficacy and safety in gastric cancer patients have been proven, but the efficacy and safety in the western real world are still lacking

Overall, between November 2015 and April 2020, 50 patients with metastatic gastric/gastroesophageal junction (GEJ) cancer who received nivolumab or pembrolizumab palliatively were included

.

Overall, between November 2015 and April 2020, 50 patients with metastatic gastric/gastroesophageal junction (GEJ) cancer who received nivolumab or pembrolizumab palliatively were included

The ORR for treatment was 10% (n = 5), while the DCR was 32% (n = 16)

OS and PFS

OS and PFS

By microsatellite status (MSS: 6.

3 vs.

By microsatellite status (MSS: 6.

By microsatellite status (MSS: 2.

The prognosis of patients with GEJ tumors was significantly better than that of patients with primary gastric tumors (median OS, 12.

Median OS was significantly shorter in patients with ECOG PS ≥ 2 than in patients with ECOG PS ≤ 1 (2.

Different subgroup analysis of OS

Different Subgroup Analysis OSDifferent Subgroup Analysis OSDifferent Subgroup Analysis OS

Metastasis time points (synchronous: 6.

3 months vs.

Metastasis time points (synchronous: 6.

Taken together, this study supports immune checkpoint inhibitor therapy in previously treated patients with metastatic gastric or gastroesophageal junction (GEJ)
.
This study supports immune checkpoint inhibitor therapy in previously treated patients with metastatic gastric or gastroesophageal junction (GEJ)
.
This study supports immune checkpoint inhibitor therapy in previously treated patients with metastatic gastric or gastroesophageal junction (GEJ)
.

Original source:

Original source:

Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Amann A, Eisterer W, Romeder F, Piringer G, Ilhan-Mutlu A, Wöll E, Greil R, Weiss L.
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
BMC Cancer.
2022 Jan 10;22(1):51.
doi: 10.
1186/s12885-021-09115-6.
PMID: 35012477; PMCID: PMC8744304.

Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Amann A, Eisterer W, Romeder F, Piringer G, Ilhan-Mutlu A, Wöll E, Greil R, Weiss L.
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
BMC Cancer.
2022 Jan 10;22(1):51.
doi: 10.
1186/s12885-021-09115-6.
PMID: 35012477; PMCID: PMC8744304.
Leave a message here